Innovative personalized medicine in gastric cancer: time to move forward
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Innovative personalized medicine in gastric cancer: time to move forward
Authors
Keywords
-
Journal
CLINICAL GENETICS
Volume 86, Issue 1, Pages 37-43
Publisher
Wiley
Online
2014-04-19
DOI
10.1111/cge.12408
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
- (2013) W. Q. Sheng et al. ANNALS OF ONCOLOGY
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
- (2013) A.F.C. Okines et al. EUROPEAN JOURNAL OF CANCER
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
- (2013) Sang Y Ha et al. MODERN PATHOLOGY
- A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
- (2013) Jeeyun Lee et al. PLoS One
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- Detection of melanoma using antibody-conjugated quantum dots in a coculture model for high-throughput screening system
- (2012) Myung Jin Kim et al. ANALYST
- A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages
- (2012) Junhun Cho et al. ANNALS OF SURGICAL ONCOLOGY
- Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer
- (2012) Jing Shi et al. BMC CANCER
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis
- (2012) A. M. Dulak et al. CANCER RESEARCH
- Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
- (2012) Sai-Hong Ignatius Ou CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
- (2012) R. Pirker et al. LUNG CANCER
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
- (2012) Zhi Jiang Zang et al. NATURE GENETICS
- Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization
- (2012) Shin-ichiro Kiyose et al. PATHOLOGY INTERNATIONAL
- High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma
- (2012) Jeeyun Lee et al. PLoS One
- ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein–Barr virus infection and microsatellite instability
- (2012) Hiroyuki Abe et al. VIRCHOWS ARCHIV
- Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Birgit Luber et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
- (2011) Kai Wang et al. NATURE GENETICS
- Epidermal growth factor receptor mutation in gastric cancer
- (2011) Zhimin Liu et al. PATHOLOGY
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Oncogenic mutations in gastric cancer with microsatellite instability
- (2010) Giovanni Corso et al. EUROPEAN JOURNAL OF CANCER
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth
- (2009) Hiroaki Mita et al. BMC CANCER
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
- (2008) M A Kim et al. HISTOPATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started